Acute psychosis induced by topiramate

Authors

  • Rajnish Raj Department of Psychiatry,Government Medical College and Rajindra Hospital,Patiala - 147 001, Punjab,India
  • Raj Kumar Department of Pharmacology, Guru Gobind Singh Medical College and Hospital, Baba Farid University of Health Sciences,Faridkot - 151 203,Punjab,India

Keywords:

Topiramate, Mania Rating Scale, Brief Psychiatric Rating Scale, Drug–drug interaction, CYP450

Abstract

Topiramate (TPM) is a new potent antiepileptic drug (AED) used as add-on therapy for generalized and partial seizures that are resistant to the other AEDs; or as a mood stabilizer, and for reducing weight gain associated with olanzapine and clozapine in patients with bipolar disorder or schizophrenia. However, there is a higher risk of psychosis with TPM in patients with a past history of psychiatric disorder. This case report highlights emergence of psychosis that was related to TPM which resolved on discontinuation.

References

Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics and mechanism of action. Epilepsia. 2000;41(Suppl 1):S3-9. [DOI via Crossref]

Marcotte D. Use of topiramate, a new anti-epileptic, as a mood stabilizer. J Affect Disorders. 1998;50:245-51. [DOI via Crossref]

Millson R, Owen J, Lorberg G, Tackaberry L. Topiramate for refractory schizophrenia. Am J Psychiatry. 2002;159:675. [DOI via Crossref]

Dursun SM, Devarajan S. Clozapine weight gain plus topiramate weight loss. Can J Psychiatry. 2000;45:198.

Levy E, Margolese HC, Chouinard G. Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. J Clin Psychiatry. 2002;63:1045. [DOI via Crossref]

Kanner AM, Wuu J, Faught E, Tatum WO 4th, Fix A, French JA, et al. A past psychiatric history may be a risk factor for topiramate-related psychiatric and cognitive adverse events. Epilepsy Behav. 2003;4(5):548-52. [DOI via Crossref]

Mula M, Trimble MR, Lhatoo SD, Sander JW. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia. 2003;44(5):659-63. [DOI via Crossref]

Betts T, Smith K, Khan G. Severe psychiatric reactions to topiramate. Epilepsia. 1997;38(Suppl 3):64.

Khan A, Faught E, Gillian F, Kuzniecky R. Acute psychotic symptoms induced by topiramate. Seizure. 1999;84:235-7. [DOI via Crossref]

Allison DB, Mentore JM, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic- induced weight gain; a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-96.

DeVane CL, Nemeroff CB. An evaluation of risperidone drug interactions. J Clin Psychopharmacol. 2001;21(4):408-16. [DOI via Crossref]

Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14(4):301-19. [DOI via Crossref]

Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32(5):554-63. [DOI via Crossref]

Downloads

Published

2017-01-02

How to Cite

Raj, R., & Kumar, R. (2017). Acute psychosis induced by topiramate. International Journal of Basic & Clinical Pharmacology, 3(2), 405–407. Retrieved from https://www.ijbcp.com/index.php/ijbcp/article/view/447

Issue

Section

Case Reports